Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

22.85
+0.06000.26%
Post-market: 22.850.00000.00%16:15 EST
Volume:277.75K
Turnover:6.47M
Market Cap:41.24M
PE:- -
High:23.94
Open:22.92
Low:22.65
Close:22.79
52wk High:28.44
52wk Low:9.60
Shares:1.80M
Float Shares:1.71M
Volume Ratio:0.66
T/O Rate:16.29%
Dividend:0.70
Dividend Rate:3.08%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Benzinga
·
3 hours ago

Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows

Reuters
·
4 hours ago

US STOCKS-Wall St heads for weekly losses as tech jitters offset inflation relief

Reuters
·
4 hours ago

Eli Lilly’s Brenipatide Trial Adds Quiet Optionality in Schizophrenia

TIPRANKS
·
5 hours ago

Roche’s New Breast Cancer Trial Pits Its Pipeline Against Eli Lilly’s Standard: What It Means for RHHBY

TIPRANKS
·
5 hours ago

Eli Lilly Prepares for Oral Weight-Loss Drug Market, Building Stockpiles Ahead of FDA Decision

Stock News
·
Yesterday

Insulet Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Yesterday

Eli Lilly & Co. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Yesterday

Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision

Reuters
·
Yesterday

Eli Lilly: Expect Medicare Beneficiaries Will Have Access to Discounted Lilly Obesity Medicines by July 1, 2026

THOMSON REUTERS
·
Yesterday

Eli Lilly: Pre-Launch Inventories Capitalized as of Dec 31, 2025 Were $1.5 Bln, Primarily Related to Orforglipron- SEC Filing

THOMSON REUTERS
·
Yesterday

Eli Lilly posts FY 2025 net income of USD 20.64 billion, up nearly double

Reuters
·
Yesterday

Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings

TIPRANKS
·
Yesterday

BUZZ-Jefferies lifts Novo Nordisk to 'hold,' sees downside risks now priced in

Reuters
·
Feb 12

Novo Nordisk plans to launch Wegovy vials

Reuters
·
Feb 12

Merck & Co. Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Feb 12

More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds

Reuters
·
Feb 12

CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating

MT Newswires Live
·
Feb 11

Eli Lilly's Intestinal Disease Treatment Mirikizumab Receives Approval in China

Stock News
·
Feb 11

Eli Lilly: Mirikizumab Approved in China for Treatment of Moderate-to-Severe Crohn's Disease and Ulcerative Colitis - Co Statement

THOMSON REUTERS
·
Feb 11